Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer - PubMed (original) (raw)
Clinical Trial
. 2003 Oct 1;95(19):1453-61.
doi: 10.1093/jnci/djg059.
Affiliations
- PMID: 14519751
- DOI: 10.1093/jnci/djg059
Clinical Trial
Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer
Giorgio V Scagliotti et al. J Natl Cancer Inst. 2003.
Abstract
Background: Surgery is the primary treatment for patients with stage I, II, or IIIA non-small-cell lung cancer (NSCLC). However, long-term survival of NSCLC patients after surgery alone is largely unsatisfactory, and the role of adjuvant chemotherapy in patient survival has not yet been established.
Methods: Between January 1994 and January 1999, 1209 patients with stage I, II, or IIIA NSCLC were randomly assigned to receive mitomycin C (8 mg/m2 on day 1), vindesine (3 mg/m2 on days 1 and 8), and cisplatin (100 mg/m2 on day 1) every 3 weeks for three cycles (MVP group; n = 606) or no treatment (control group; n = 603) after complete resection. Randomization was stratified by investigational center, tumor size, lymph-node involvement, and the intention to perform radiotherapy. The primary endpoint was overall survival and secondary endpoints were progression-free survival and toxicity associated with adjuvant treatment. Survival curves were analyzed using the log-rank test. All statistical tests were two-sided.
Results: After a median follow-up time of 64.5 months, there was no statistically significant difference between the two patient groups in overall survival (hazard ratio = 0.96, 95% confidence interval = 0.81 to 1.13; P =.589) or progression-free survival (hazard ratio = 0.89, 95% confidence interval = 0.76 to 1.03; P =.128). Only 69% of patients received the three planned cycles of MVP. Grades 3 and 4 neutropenia occurred in 16% and 12%, respectively, of patients in the MVP arm. Radiotherapy was completed by 65% of patients in the MVP arm and by 82% of patients in the control group. In the multivariable analysis, only disease stage and sex were associated with survival.
Conclusion: This randomized trial failed to prospectively confirm a statistically significant role for adjuvant chemotherapy in completely resected NSCLC. Given the poor compliance with the MVP regimen used in this study, future studies should explore more effective treatments.
Comment in
- Adjuvant chemotherapy for non-small-cell lung cancer: the end of the beginning.
Johnson BE. Johnson BE. J Natl Cancer Inst. 2003 Oct 1;95(19):1422-4. doi: 10.1093/jnci/djg077. J Natl Cancer Inst. 2003. PMID: 14519741 Review. No abstract available.
Similar articles
- Vinorelbine plus cisplatin versus cisplatin plus vindesine and mitomycin C in stage IIIB-IV non-small cell lung carcinoma: a prospective randomized study.
Gebbia V, Galetta D, Riccardi F, Gridelli C, Durini E, Borsellino N, Gebbia N, Valdesi M, Caruso M, Valenza R, Pezzella G, Colucci G; Gruppo Oncologico Italia Meridionale. Gebbia V, et al. Lung Cancer. 2002 Aug;37(2):179-87. doi: 10.1016/s0169-5002(02)00076-4. Lung Cancer. 2002. PMID: 12140141 Clinical Trial. - Postoperative adjuvant cisplatin, vindesine, plus uracil-tegafur chemotherapy increased survival of patients with completely resected p-stage I non-small cell lung cancer.
Imaizumi M; Study Group of Adjuvant Chemotherapy for Lung Cancer (Chubu, Japan). Imaizumi M, et al. Lung Cancer. 2005 Jul;49(1):85-94. doi: 10.1016/j.lungcan.2004.11.025. Lung Cancer. 2005. PMID: 15949594 Clinical Trial. - Mitomycin C plus vindesine plus etoposide (MEV) versus mitomycin C plus vindesine plus cisplatin (MVP) in stage IV non-small-cell lung cancer: A phase III multicentre randomised trial. The "Gruppo Oncologico Centro-Sud-Isole' (G.O.C.S.I.).
Gridelli C, Perrone F, Palmeri S, D'Aprile M, Cognetti F, Rossi A, Gebbia V, Pepe R, Veltri E, Airoma G, Russo A, Incoronato P, Scinto AF, Palazzolo G, Natali M, Leonardi V, Gallo C, De Placido S, Bianco AR. Gridelli C, et al. Ann Oncol. 1996 Oct;7(8):821-6. doi: 10.1093/oxfordjournals.annonc.a010761. Ann Oncol. 1996. PMID: 8922196 Clinical Trial. - A randomized study of two vindesine plus cisplatin-containing regimens with the addition of mitomycin C or ifosfamide in patients with advanced non-small cell lung cancer.
Rosell R, Abad-Esteve A, Moreno I, Barnadas A, Carles J, Fernandez C, Ribelles N, Culubret M. Rosell R, et al. Cancer. 1990 Apr 15;65(8):1692-9. doi: 10.1002/1097-0142(19900415)65:8<1692::aid-cncr2820650805>3.0.co;2-x. Cancer. 1990. PMID: 2156597 Review. - Compliance with post-operative adjuvant chemotherapy in non-small cell lung cancer. An analysis of National Cancer Institute of Canada and intergroup trial JBR.10 and a review of the literature.
Alam N, Shepherd FA, Winton T, Graham B, Johnson D, Livingston R, Rigas J, Whitehead M, Ding K, Seymour L. Alam N, et al. Lung Cancer. 2005 Mar;47(3):385-94. doi: 10.1016/j.lungcan.2004.08.016. Lung Cancer. 2005. PMID: 15713522 Review.
Cited by
- Management of Non-Metastatic Non-Small Cell Lung Cancer (NSCLC) with Driver Gene Alterations: An Evolving Scenario.
Fuorivia V, Attili I, Corvaja C, Asnaghi R, Carnevale Schianca A, Trillo Aliaga P, Del Signore E, Spitaleri G, Passaro A, de Marinis F. Fuorivia V, et al. Curr Oncol. 2024 Aug 30;31(9):5121-5139. doi: 10.3390/curroncol31090379. Curr Oncol. 2024. PMID: 39330007 Free PMC article. Review. - A narrative review on perioperative systemic therapy in non-small cell lung cancer.
Hsu R, Arter ZL, Poei D, Benjamin DJ. Hsu R, et al. Explor Target Antitumor Ther. 2024;5(4):931-954. doi: 10.37349/etat.2024.00256. Epub 2024 Jul 26. Explor Target Antitumor Ther. 2024. PMID: 39280253 Free PMC article. Review. - Real-world efficacy of adjuvant therapy for totally resected stage I lung adenocarcinoma patients with pathological high-risk factors: propensity score analysis.
Zhao K, Yang L, Liu L, Wang G, Zhang J, Gao X, Guo C, Huang C, Chen Y, Li S. Zhao K, et al. BMC Surg. 2024 May 8;24(1):140. doi: 10.1186/s12893-024-02428-w. BMC Surg. 2024. PMID: 38720305 Free PMC article. - New systemic treatment paradigms in resectable non-small cell lung cancer and variations in patient access across Europe.
Houda I, Dickhoff C, Uyl-de Groot CA, Reguart N, Provencio M, Levy A, Dziadziuszko R, Pompili C, Di Maio M, Thomas M, Brunelli A, Popat S, Senan S, Bahce I. Houda I, et al. Lancet Reg Health Eur. 2024 Mar 4;38:100840. doi: 10.1016/j.lanepe.2024.100840. eCollection 2024 Mar. Lancet Reg Health Eur. 2024. PMID: 38476748 Free PMC article. Review. - Adjuvant chemotherapy in pathological node-negative non-small cell lung cancer.
Cheng YF, Chen YL, Liu CC, Lin CM, Tong SS, Wang BY. Cheng YF, et al. Sci Rep. 2023 Nov 6;13(1):19137. doi: 10.1038/s41598-023-46679-8. Sci Rep. 2023. PMID: 37932436 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous